Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comme...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s in...
First-in-class oral therapy ATR-258 mimics the effects of exercise – driving fat loss, increasing muscle, and improving metabolism – with b...
Upfront cash fee with total value of $7.0 million, comprised of a $3.5 million cash payment and $3.5 million in-kind payment in the form of a trans...
Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal ad...
New panel expands coverage for Alzheimer’s and Parkinson’s diseases including 15 new biomarkers developed with support from The Michael J. Fo...
First study to demonstrate safe and selective administration of sustained and localized delivery of enzalutamide -Alessa Therapeutics (“...
Study designed to support potential label expansion into additional settings of cholestatic pruritus - Topline data expected in Q4 2026 Mirum...
- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced immunosu...
YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug ...
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery...
KOMO Biosciences, a developer of non-viral targeted insertion technologies, today announced that it has granted Syngenta, a world leader in agricultural ...
Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and developm...
© 2026 Biopharma Boardroom. All Rights Reserved.
